Your browser doesn't support javascript.
loading
Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy.
Kharlip, J; Salvatori, R; Yenokyan, G; Wand, G S.
Affiliation
  • Kharlip J; Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21201, USA. jkharlip@gmail.com
J Clin Endocrinol Metab ; 94(7): 2428-36, 2009 Jul.
Article in En | MEDLINE | ID: mdl-19336508
ABSTRACT
CONTEXT Recurrence of hyperprolactinemia after cabergoline withdrawal ranges widely from 36 to 80%. The Pituitary Society recommends withdrawal of cabergoline in selected patients.

OBJECTIVE:

Our aim was to evaluate recurrence of hyperprolactinemia in patients meeting The Pituitary Society guidelines.

DESIGN:

Patients were followed from the date of discontinuation to either relapse of hyperprolactinemia or the day of last prolactin test.

SETTING:

We conducted the study at an academic medical center. PATIENTS Forty-six patients meeting Pituitary Society criteria (normoprolactinemic and with tumor volume reduction after 2 or more years of treatment) participated in the study.

INTERVENTIONS:

After withdrawal, if prolactin returned above reference range, another measurement was obtained within 1 month, symptoms were assessed by questionnaire, and magnetic resonance imaging was performed. MAIN OUTCOME

MEASURES:

We measured risk of and time to recurrence estimates as well as clinical predictors of recurrence.

RESULTS:

Mean age of patients was 50 +/- 13 yr, and 70% were women. Thirty-one patients had microprolactinomas, 11 had macroprolactinomas, and four had nontumoral hyperprolactinemia. The overall recurrence was 54%, and the estimated risk of recurrence by 18 months was 63%. The median time to recurrence was 3 months (range, 1-18 months), with 91% of recurrences occurring within 1 yr after discontinuation. Size of tumor remnant prior to withdrawal predicted recurrence [18% increase in risk for each millimeter (95% confidence interval, 3-35; P = 0.017)]. None of the tumors enlarged in the patients experiencing recurrence, and 28% had symptoms of hypogonadism.

CONCLUSIONS:

Cabergoline withdrawal is practical and safe in a subset of patients as defined by The Pituitary Society guidelines; however, the average risk of long-term recurrence in our study was over 60%. Close follow-up remains important, especially within the first year.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperprolactinemia / Withholding Treatment / Ergolines Type of study: Diagnostic_studies / Etiology_studies / Evaluation_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Pregnancy Language: En Journal: J Clin Endocrinol Metab Year: 2009 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hyperprolactinemia / Withholding Treatment / Ergolines Type of study: Diagnostic_studies / Etiology_studies / Evaluation_studies / Guideline / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Pregnancy Language: En Journal: J Clin Endocrinol Metab Year: 2009 Document type: Article Affiliation country: Estados Unidos
...